⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVPH News
Reviva Pharmaceuticals Holdings, Inc. Common Stock
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
globenewswire.com
RVPH
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
globenewswire.com
RVPH
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
globenewswire.com
RVPH
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
globenewswire.com
RVPH
Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
globenewswire.com
RVPH
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
globenewswire.com
RVPH
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
globenewswire.com
RVPH
Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference
globenewswire.com
RVPH